Neeraj Agarwal: Breaking news: Glad to report the news from ph3 Contact-2 trial Cabozantinib + atezolizumab significantly improved outcomes in mCRPC prostate cancer.
Neeraj Agarwal stated on Twitter:
“Breaking news: Glad to report the news from ph3 Contact-2 trial Cabozantinib + atezolizumab significantly improved outcomes in mCRPC prostate cancer. Trial description from ASCO TIP abstract Press release: http://shorturl.at/cCQY4”
Source: Neeraj Agarwal/Twitter
Neeraj Agarwal is a Professor of medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI. Dr. Agarwal is an Advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration, leads early therapeutics in the SWOG genitourinary cancers committee, and is the Chief Editor of ASCO Daily News.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023